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HypothermiaIn 1977 at the age of nine, I was diagnosed with Ewing sarcoma of the left ﬁbula. At that time, the therapeutic
strategy for Ewing sarcoma was being established. I was treated with multi-drug chemotherapy (Doxorubicin
490mg, Vincristine 22.3mg, Cyclophosphamide 10.8 g, and Dactinomycin 13,500mcg), external beam radiation
(54.0 Gy), and surgical excision (partial ﬁbulectomy). This essay discusses the diagnosis and treatment of late
effects of cancer therapy from a physician–patient's perspective. Six areas of clinical care and research are
addressed: limb pain, systemic effects, hypothermia, pathology, genetics, and exercise.
© 2015 The Author. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Childhood
In 1977 at the age of nine, I was diagnosed with Ewing sarcoma of
the left ﬁbula. At that time, the therapeutic strategy for Ewing sarcoma
was being established. I was treated with multi-drug chemotherapy
(Doxorubicin 490 mg, Vincristine 22.3 mg, Cyclophosphamide 10.8 g,
and Dactinomycin 13,500 mcg), external beam radiation (54.0 Gy),
and surgical excision (partial ﬁbulectomy).
An ofﬁce visit for chemotherapy was brief. A lab technician pricked
my ﬁnger andmouth-pipetted a small quantity of blood for a peripheral
smear. After an oncologist reviewed the smear, I was brought into a pri-
vate examroom.A fellowor attending asked how Iwas andperformed a
brief physical exam. If my cell counts were adequate, the physician tied
a tourniquet on my arm and personally injected chemo via a syringe
into a peripheral vein. With Adriamycin, emesis started while the
needle was still in my arm. With Cyclophosphamide, emesis started
hours later. On occasion, chemotherapy extravasated, blackening the
dorsum of the injected hand(s).
Treated for eighteenmonths, I wore awig for over a year. Therewere
no IV ﬂuids, no growth factors, no effective anti-emetics, no prophylac-
tic antibiotics, and no cardioprotective agents. There were no central
venous access lines, no orthopedic endoprostheses, and no tattoos to
mark radiation ﬁelds. There was no general anesthesia for a bone
marrow aspirate. There was no prescription toothpaste for dry mouth.
There was no Make-a-Wish Foundation; no summer camps with
medical oversight. The ﬁrst Ronald McDonald House had opened in
1974 far away in Philadelphia.
I once read I had a 50% chance of surviving to age 21. I had no doubt
that I would live. I didn't have a single complication: no woundand Ltd. This is an open access articledehiscence, stomatitis, weight loss, seizure, amenorrhea, infection,
cystitis, neuropathy, blood transfusion, or cardiac dysfunction. With
clear scans at my ﬁve-year follow up, I was considered cured.
2. Adulthood
In the fall of 2003, I began to have trouble with my left leg. At the
time I was a healthy and active chief resident in Anatomic Pathology.
Over time, I realized that I also had systemic symptoms when my leg
acted up. Eventually, I developed somewhat inconvenient, spontaneous
spells characterized by hypothermia, hypotension, dyspnea, tachypnea,
polyuria, dysarthria, profound fatigue, sleepiness, and stupor which
lasted minutes to hours.
Several episodes were witnessed by clinicians. In March 2013, my
primary care physician documented: “Pt looked well at start of visit.
About 20 min into visit became ﬂushed. VS were stable but BP and
pulse dropped signiﬁcantly. She was slow to respond, but intelligible,
and speech was slightly garbled. [T]remors [present]. Left leg was cool
but cap reﬁll in foot was normal. Symptoms mostly resolved within 30
mins. Vitals: BP 130/70 mm Hg; P: 73 bpm; R: 14 bpm; O2 Sat.: 100%
(room air). Repeat BP: 108/62mmHg; P: 62 bpm. RESPIRATORY:mildly
tachypneic, normal breath sounds with no rales, rhonchi, wheezes or
rubs. CARDIOVASCULAR: normal rate and rhythm without murmurs;
normal S1 and S2 heart soundswith no S3, S4, rubs, or clicks. PSYCHIAT-
RIC: Orientation: responsive to vocal stimuli; patient was transiently
slightly stuporous.”
With extensive workups, my problem list grew: 2 cm osteochondral
lesion, left talar dome; Complex Regional Pain Syndrome (formerly Re-
ﬂex Sympathetic Dystrophy or RSD), left lower extremity; symptomatic
uterine ﬁbroids; recurrent erythema multiforme; severe peripheral
vasospasm below the left knee (2004); chronic fatigue, dyspnea
(2005); left sartorius muscle tendonitis, vitamin D deﬁciency (2008);
osteopenia; tubular adenoma (2010); Bartholin gland cyst (2011);under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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autonomic dysfunction NOS; episodic right eyebrow and lid ptosis;
endogenous hypothermia; borderline elevation of pulmonary artery
pressure (2013); three basal cell carcinomas, irradiated left leg; left
breast cancer: sentinel lymph node negative, 1.3 cm, poorly differenti-
ated, invasive ductal carcinoma positive for Estrogen Receptor (ER+),
Progesterone Receptor (PR+), and HER2/neu (triple positive breast
cancer) (2014); and sessile serrated adenoma (2015).
At the time of the breast cancer diagnosis in March 2014, I was
deconditioned and vulnerable to any physical manipulations. With
prior cytostatic and cardiotoxic chemotherapy, I had a real but unknown
risk for congestive heart failure and a therapy-related myeloid
neoplasm. I wanted to avoid radiation to the heart and minimize any
surgical intervention. I declined neoadjuvant therapy with trastuzumab
and pertuzumab due to the risk of preoperative heart failure. Further, I
wanted accurate pathological staging with minimal risk of a false nega-
tive sentinel lymph node biopsy. [1] While waiting for a May surgery
date, I worked with a personal trainer to strengthen my core muscles
as well as increase my caloric and protein intake. Fortunately, I was a
candidate for skin-sparing, nipple-sparing, simple mastectomy with
single-stage implant reconstruction. With wide surgical margins and a
sentinel lymph node negative for tumor, radiation was not indicated.
The physical trainingwas surprisingly beneﬁcial. With stronger abdom-
inal and thigh muscles, I did not need my arms to sit or stand. By doing
crunches, I avoided incisional pain and stopped using painkillers quite
quickly.
In June 2014, I began seventeen rounds of trastuzumab and six
rounds of docetaxel and carboplatin. Tamoxifen started in November.
My ﬁrst day in the chair did not go well. Sitting a long time before the
IV ﬂuids and steroids started, I couldn't see any pink puke basins
anywhere in the infusion room. It was uncomfortable to be surrounded
by cancer patients. We were lined up rather closely in reclining chairs,
our backs to the windows. Patients wore summer time shorts and
dresses. I could see the fatigued pallor of anemia in an older gentleman:
Leukemia? Myelodysplasia? Marrow replacing metastases? A middle-
aged woman had bipedal edema which appeared pitting up to at least
mid-calf. Kidney failure? Heart failure? Deep vein thromboses? A man
with dusky legs appeared surprisingly young and trim for vascular
insufﬁciency. A woman's blouse was folded over an insulin pump. I
had to shut out the nurses' chemo checks. I didn't want to hear the
patient name, the date of birth, the drug, and the infusion rate. It was
too easy to guess the diagnosis.
Once the drug infusions started,many ofmy chronic issuesﬂared up.
With trastuzumab, I was extremely cold with pain, shortness of breath,
difﬁculty concentrating, speaking, and walking. With docetaxel, I felt
cold ﬂuid drop straight from the port down tomy left leg causing burn-
ing (toes), myalgias (thigh), and bone pain (ankle, hip). The infusion
was stopped twice. Vital signs were stable, although they didn't check
my temperature. With carboplatin, my thoughts cleared. I had my
usual substernal chest pain. At discharge, patient transport brought a
wheelchair. I apologized while I swatted her hand from my left foot.
“Please don't touch my leg. It is really sensitive.” At home I wrapped
up in a down comforter. Oral thermometers read 34.8 °C, 35.3 °C
(94.6 °F, 95.6 °F). I didn't puke.
This recent treatment year had a few surprises. After discussing
strategy with several colleagues, I took 300 mg gabapentin in the eve-
ning and the morning before cytostatic therapy. During infusions I
stood up every hour to walk or stretch. While infusion days improved
dramatically, some side effects became troublesome. I had recurrent
bouts of sterile dysuria where I could feel and see urethral mucosa pro-
lapse and regress. Admittedly self-diagnosed, I wonderedwhether prior
cyclophosphamide predisposed to urethral caruncle and a slippery
urothelium. With worsening neuropathies, walking became difﬁcult.
Cytostatic chemotherapy was stopped after ﬁve cycles.
Starting in the fall of 2014, I occasionally experienced heat-related
pruritus and dermatographism triggered by physical exertion, hotdrinks, warm showers, night sweats, and hot ﬂashes. Of concern, hypo-
thermic episodes persisted for days andweeks inDecember and January
keeping me housebound for most of two months. For an episode of
marked dyspnea and chest tightness in December I tried an albuterol
inhaler. Within 30 min, I was shaking cold with an oral temperature of
35.0 °C (95.0 °F). Charting vital signs, I noticed that stimuli such as
snow shoveling, housecleaning, springtime yard work or marked pain
were associated with oral temperatures ≤35.0 °C (95.0 °F). A three-
month, springtime trial of clomipramine for thermal regulation was
unsuccessful.
3. A Physician-Patient Perspective
Cancer has strong connotations of debilitation, anorexia, fatigue,
pain and premature death. There is often a sense of otherness with can-
cer patients. They are no longer among the livingwell.Weary physicians
who treat cancer patients may expect survivors to deal with discomfort
or unpleasantness. “There isn't much we can do.” “You are lucky to be
alive.” There are six areas where clinicians can make a positive differ-
ence for cancer survivors.
1) Limb pain
The effects of cancer therapy are multifactorial and multi-systemic.
Limb pain may be secondary to neuropathy (radiation, vincristine, sur-
gery), vasculopathy (radiation, chemotherapy), arthropathy (surgery),
skeletal growth anomalies (surgery, radiation, endocrine disturbance),
bone thinning/fractures (radiation, endocrine disturbance), second
malignant neoplasms (radiation), gait/posture anomalies, and/or
lymphedema (surgery, radiation). [2–6].
Evaluation of limb pain at academic centers or cancer centers may
begin and end with ruling out neoplasia. Radiology reports may be
succinct: “No evidence of neoplasia, changes consistent with treatment
effect.”
Other disciplines have unique approaches to limb pain. For example,
private sports medicine clinics treat high performance athletes follow-
ing trauma. These athletes can be very demanding, wanting to return
to their former level of functioning. They expect their physicians to
identify and ﬁx all of the problems in a limb. In these groups, radiology
reports can detail every abnormality of eachmuscle, bone, joint, tendon,
and ligament. This is the starting point for amultidisciplinary evaluation
and treatment program which may involve nerve conduction studies,
steroid injections, surgery and highly experienced physical therapy.
Alternatively, some chronic pain patients beneﬁt tremendously from
inpatient rehabilitation programs. The two week program for patients
with Complex Regional Pain Syndrome at the Royal National Hospital
for Rheumatic Diseases in Bath, UK is a superlative example. In addition
to intense physical therapy, hydro-therapy, desensitization, andmirror-
feedback, they provide comprehensive education on everyday coping
skills such as assistive devices, assertive communication, navigating
errands, relaxation techniques, activity pacing, and sleep hygiene.
2) Systemic symptoms
Survivors with systemic symptoms such as chest pain or dyspnea
may have multiple late effects contributing to their symptoms. There
is strong evidence that chemotherapy and radiation contribute to
coronary artery disease [7–11], cardiomyopathy [9,11,12], valvular
heart disease [11,12], congestive heart failure [7–9,13], stroke [7,9,11],
hypertension [8,12] thromboembolism [8], pulmonary disease [9,11,
12], kidney disease [7,11–13], vasculopathy [3], neuropathy [2,11–13],
endocrine disorders [9,11,12], second malignant neoplasms [7,9,12,
13], and autonomic dysfunction. [2,14–20].
Ideally, one physician or team would coordinate a comprehensive,
multidisciplinary workup of cancer treatment effects. The evaluation
of episodic symptoms could be facilitated by the growing number of
portable, FDA-approved devices: pulse oximeters, pulmonary
peak ﬂow meters, ingestible thermometer pills, handheld three-lead
EKGs, and monitors for cardiac output, skin conductance, and skin
temperature.
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Adult survivors of childhood cancer have described temperature
dysregulation, such as variable episodes of hypothermia (Larissa
Nekhlyudov, personal communication). Is hypothermia a side effect of
chemotherapy? If it is, do cancer survivors have a unique or stereotypi-
cal presentation of hypothermia?
Hypothermia is deﬁned as a core body temperature below 35.0 °C
(95.0 °F). The incidence of endogenous hypothermia is uncertain be-
cause low body temperature often goes unnoticed. The manifestations
of hypothermia vary from mild to severe [21–23]. Initial responses to
cold include hypertension, tachycardia, tachypnea, and vasoconstriction
[21]. Signs and symptoms of hypothermia include confusion [22],
cognitive decline [21,22,24–27], stupor [23], agitation [22], memory
deﬁcits [24,25,27], lethargy [24], drowsiness [24], slurred speech [23,
24], stumbling gait [23,24], tremor [23,27], bradycardia [21–23,26,27],
hypotension [21,23,26], profuse sweating [22,23,25–27], ﬂushing [22,
26], cold diuresis [21], hypovolemia [21] and hematologic abnormalities
[23,24,28]. Treatment thus far is empiric with some efﬁcacy reported
with clomipramine, cyproheptadine, or clonidine [27].
Periodic hypothermia has been reported withmultiple medical con-
ditions. It is associated with neurologic lesions such as agenesis of the
corpus callosum (Shapiro syndrome) [23,26–28], brain tumors [23,24,
27,29,30], central nervous system trauma [21,24], multiple sclerosis
[22], stroke [27], and immune-mediated encephalitis [25]. Hypothermia
has been described with burns, toxins, sepsis, and endocrine disorders
[21]. Low core body temperature has been noted in case reports of
Hodgkin lymphoma [31] and mastocytosis [32].
Despite extensive research on thermoregulation, the pathophysiolo-
gy of periodic hypothermia remains incompletely understood [21,33].
Screening and studying cancer survivors may provide new insights
into thermal regulation as well as possible treatments for endogenous
hypothermia.
4) Pathology
What are the histologic features of trastuzumab- or bevacizumab-
associated cardiac dysfunction [8,34]? Do anthracyclines induce
increased iron uptake in human HFE± hearts (liver, pancreas, pituitary
gland) [35,36]? How prevalent are abnormalities of cardiac nerves and
ganglia following chemotherapy [37]? Studies of endomyocardial
biopsies and heart explants [38] could provide useful insights into the
pathogenesis of cardiotoxicity.
5) Genetics
Currently, new cancer patients are screened only for familial cancer
syndromes. Patients could also be screened for familial cardiovascular
disease. In the future, patients may be screened for susceptibility to
chemotherapy toxicity such as cardiovascular toxicity [35,39,40], hot
ﬂashes, [41] and neuropathy [42].
6) Exercise
The beneﬁts of exercise can't be overstated. Exercise can decrease
pain, fatigue, and sleep disturbance. Optimal health involves both
engaging in activity and minimizing prolonged sitting or lying down
[43,44]. Infusion centers should not resemble TB sanatoriums with
rows of patients reclining quietly in their chairs, covered by a blanket.
Patients should be encouraged to move, stretch, stand, and walk, both
at home and in the clinic. Everyone should be encouraged to be as active
as possible [45].4. Conclusions
I am among the ﬁrst generation of childhood cancer survivors. There
will be growing numbers of us seeking help from primary care physi-
cians, oncologists, cardiologists, surgeons, and other specialists.My con-
cern for cancer survivors is that our complex medical histories may be
incompletely evaluated leading to under-, over- or mal-treatment.
With increasing numbers of new cancer patients, who will stand up
for survivors? Will patients ﬂounder, bouncing from one subspecialistto another? My hope is that survivors won't accept a faulty verdict:
“There is nothing that can be done.”
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